Skip to main content
Premium Trial:

Request an Annual Quote

Roche ALK Test Gains FDA Approval as CDx for Alecensa

NEW YORK (360Dx) –  Roche said today that the US Food and Drug Administration has approved its Ventana ALK (D5F3) companion diagnostic as an aid in identifying ALK-positive non-small cell lung cancer patients who would benefit from treatment with the firm's drug Alecensa (alectinib).

"This immunohistochemistry assay will deliver critical information on treatment options for non-small cell lung cancer patients," Ann Costello, head of Roche tissue diagnostics, said in a statement. "The ability to identify ALK-positive patients very quickly with a simple IHC test ensures that more patients can benefit from targeted therapy."

The detection and inhibition of the ALK biomarker found in NSCLC can help shrink tumors in some ALK-positive patients, the firm added.

The Ventana ALK (D5F3) CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.

The ALK test also gained FDA approval in June 2017 as a CDx to identify best responders to Novartis' NSCLC drug Zykadia (ceritinib) in June 2017, and gained FDA approval in June 2015 as a CDX to identify NSCLC patients who are likely to respond well to Pfizer's Xalkori (crizotinib).

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.